The impact of the new Global Lung Function Initiative T LCO reference values on trial inclusion for patients with idiopathic pulmonary fibrosis
- PMID: 30760543
- DOI: 10.1183/13993003.01895-2018
The impact of the new Global Lung Function Initiative T LCO reference values on trial inclusion for patients with idiopathic pulmonary fibrosis
Conflict of interest statement
Conflict of interest: M. Wapenaar has nothing to disclose. Conflict of interest: J.R. Miedema has nothing to disclose. Conflict of interest: C.J. Lammering has nothing to disclose. Conflict of interest: F.W. Mertens has nothing to disclose. Conflict of interest: M.S. Wijsenbeek reports institutional fees and grants from Boehringer Ingelheim and Hoffman la Roche, and institutional fees from Galapagos, outside the submitted work.
Comment on
-
Launching Global Lung Function Initiative reference values in Belgium: tips and tricks.Eur Respir J. 2018 Aug 2;52(2):1800922. doi: 10.1183/13993003.00922-2018. Print 2018 Aug. Eur Respir J. 2018. PMID: 30072542 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources